Verification evidence is still being completed.
PDF / print export
ADC Therapeutics SA
Epalinges, Switzerland
- Verified lead
- Ameet Mallik
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Antibody-Drug Conjugates, Loncastuximab Tesirine, and Commercial Oncology Operations
- Review cycle
- 24 April 2026
- Full address
- Route de la Corniche 3B, 1066 Epalinges, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- ADC Therapeutics official Leadership Team page confirming Ameet Mallik as Chief Executive Officer.
- Editorial note
- Epalinges NYSE-listed commercial-stage ADC biotech with named CEO, FDA-approved Zynlonta in DLBCL, and an expanding oncology pipeline.
Antibody-Drug Conjugates, Loncastuximab Tesirine, and Commercial Oncology Operations
NYSE ADCT listing, FDA Zynlonta approval, Swiss Biotech Association membership
Epalinges NYSE-listed commercial-stage ADC biotech with named CEO, FDA-approved Zynlonta in DLBCL, and an expanding oncology pipeline.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Epalinges, Switzerland
ADC Therapeutics SA
Antibody-Drug Conjugates, Loncastuximab Tesirine, and Commercial Oncology Operations · Commercial ADC oncology
Epalinges NYSE-listed commercial-stage ADC biotech with named CEO, FDA-approved Zynlonta in DLBCL, and an expanding oncology pipeline.
- Lead
- Ameet Mallik (verified ↗)
- Address
- Route de la Corniche 3B, 1066 Epalinges, Switzerland (source ↗)
- Compliance
- FDA Zynlonta approval
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Commercial ADC oncology
- Capabilities
- Commercial Oncology ADC · Antibody-Drug Conjugate R&D · Clinical Pipeline Expansion
- Founded
- 2011
- Headcount
- 201-500
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Ameet Mallik
Chief Executive Officer
Full addressRoute de la Corniche 3B, 1066 Epalinges, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Commercial ADC oncology
Epalinges, Switzerland. Antibody-Drug Conjugates, Loncastuximab Tesirine, and Commercial Oncology Operations. Review completed on 24 Apr 2026.
Swissmedic, FDA, and EMA for commercial and clinical oversight
NYSE ADCT listing, FDA Zynlonta approval, Swiss Biotech Association membership
Antibody-Drug Conjugates, Loncastuximab Tesirine, and Commercial Oncology Operations
Epalinges NYSE-listed commercial-stage ADC biotech with named CEO, FDA-approved Zynlonta in DLBCL, and an expanding oncology pipeline.
Editorial note
ADC Therapeutics is one of Switzerland's largest commercial-stage biotechs, NYSE-listed, with a named CEO, a marketed oncology ADC (Zynlonta), and headquarters in Epalinges close to Lausanne.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Commercial Oncology ADC
Antibody-Drug Conjugate R&D
Clinical Pipeline Expansion
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
ADC design and characterization
Clinical and commercial operations
NYSE investor infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- VERIFIED ACTIVE 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is ADC Therapeutics SA located?
- ADC Therapeutics SA operates from Route de la Corniche 3B, 1066 Epalinges, Switzerland, Epalinges, Switzerland.
- Who runs ADC Therapeutics SA?
- ADC Therapeutics SA is led by Ameet Mallik, Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does ADC Therapeutics SA hold?
- ADC Therapeutics SA is documented under FDA Zynlonta approval.
- What does ADC Therapeutics SA do?
- Epalinges NYSE-listed commercial-stage ADC biotech with named CEO, FDA-approved Zynlonta in DLBCL, and an expanding oncology pipeline. Core capabilities: Commercial Oncology ADC, Antibody-Drug Conjugate R&D, Clinical Pipeline Expansion.
Editorial context
Related technical briefs
Briefs that name Epalinges as a covered market or city.